Neurocrine Biosciences Inc.
(64125C109)
ファンドの報告 Neurocrine Biosciences Inc. 13F提出書類による
| 商号 | 保有株式/元本 | 市場価格 | オプション | 報告期間 | 有効日 |
|---|---|---|---|---|---|
| Healthcor Management LP | 2,371,390 | $200,216k | Jun 30, 2019 | Aug 14, 2019 | |
| Orbimed Advisors LLC | 1,833,200 | $154,777k | Jun 30, 2019 | Aug 14, 2019 | |
| Baker BROS Advisors LP | 1,415,283 | $119,492k | Jun 30, 2019 | Aug 14, 2019 | |
| Point72 Asset Management LP | 1,124,684 | $94,957k | Jun 30, 2019 | Aug 14, 2019 | |
| Rock Springs Capital Management LP | 1,023,000 | $86,372k | Jun 30, 2019 | Aug 14, 2019 | |
| DSM Capital Partners LLC | 660,524 | $55,767k | Jun 30, 2019 | Aug 14, 2019 | |
| Eventide Asset Management LLC | 353,000 | $29,804k | Jun 30, 2019 | Aug 14, 2019 | |
| Tekla Capital Management LLC | 207,078 | $17,484k | Jun 30, 2019 | Aug 14, 2019 | |
| Sofinnova Ventures Inc | 66,638 | $5,626k | Jun 30, 2019 | Aug 13, 2019 | |
| Dafna Capital Management LLC | 64,608 | $5,455k | Jun 30, 2019 | Aug 14, 2019 | |
| Sivik Global Healthcare LLC | 40,000 | $3,377k | Jun 30, 2019 | Aug 14, 2019 | |
| Nicholas Investment Partners LP | 33,990 | $2,870k | Jun 30, 2019 | Aug 9, 2019 | |
| Atika Capital Management LLC | 23,313 | $1,968k | Jun 30, 2019 | Aug 12, 2019 | |
| Capital Impact Advisors LLC | 20,923 | $1,724k | Jun 30, 2019 | Jul 19, 2019 | |
| Woodstock Corporation | 14,880 | $1,256k | Jun 30, 2019 | Jul 3, 2019 | |
| Tocqueville Asset Management LP | 14,755 | $1,246k | Jun 30, 2019 | Jul 31, 2019 | |
| Grandfield & DODD LLC | 8,611 | $727k | Jun 30, 2019 | Jul 29, 2019 | |
| Allen Investment Management LLC | 8,147 | $688k | Jun 30, 2019 | Aug 12, 2019 | |
| Redmile Group LLC | 2,740 | $231k | Jun 30, 2019 | Aug 14, 2019 | |
| Brandywine Managers LLC | 2,700 | $228k | Jun 30, 2019 | Aug 13, 2019 | |
| Wespac Advisors Socal LLC | 2,465 | $208k | Jun 30, 2019 | Jul 30, 2019 | |
| QS Investors LLC | 2,341 | $198k | Jun 30, 2019 | Aug 14, 2019 |